AR052301A1 - Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas - Google Patents

Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas

Info

Publication number
AR052301A1
AR052301A1 ARP050101278A ARP050101278A AR052301A1 AR 052301 A1 AR052301 A1 AR 052301A1 AR P050101278 A ARP050101278 A AR P050101278A AR P050101278 A ARP050101278 A AR P050101278A AR 052301 A1 AR052301 A1 AR 052301A1
Authority
AR
Argentina
Prior art keywords
compound
formula
preparation
pharmaceutical compositions
crystal forms
Prior art date
Application number
ARP050101278A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0407521A external-priority patent/GB0407521D0/en
Priority claimed from GB0411688A external-priority patent/GB0411688D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR052301A1 publication Critical patent/AR052301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formas cristalinas y composiciones farmacéuticas. Reivindicacion 1: Un procedimiento para la preparacion de una sal monoclorhidrato del compuesto de formula (1), en la que *C y **C denota átomos de carbono asimétricos, tal procedimiento comprende las etapas de: a) poner en contacto un compuesto de formula (2), en la que P1 representa un grupo protector de hidroxilo, y P2 y P3 representa cada uno independientemente hidrogeno o un grupo protector; con un ácido débil, para efectuar la protonacion selectiva; b) poner en contacto el producto de a) con una fuente de iones cloruro para efectuar el intercambio de aniones; c) desproteccion para eliminar P1, y cuando sea necesario P2 y P3; d) aislamiento del compuesto de formula (1) como el monoclorhidrato; y de forma opcional; e) cristalizacion o recristalizacion del compuesto de formula (1).
ARP050101278A 2004-04-02 2005-03-31 Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas AR052301A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0407521A GB0407521D0 (en) 2004-04-02 2004-04-02 Chemical process
GB0411688A GB0411688D0 (en) 2004-05-25 2004-05-25 Chemical process
US57446704P 2004-05-26 2004-05-26

Publications (1)

Publication Number Publication Date
AR052301A1 true AR052301A1 (es) 2007-03-14

Family

ID=34963396

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101278A AR052301A1 (es) 2004-04-02 2005-03-31 Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas

Country Status (13)

Country Link
US (1) US7846973B2 (es)
EP (1) EP1730104A1 (es)
JP (1) JP2007530652A (es)
AR (1) AR052301A1 (es)
AU (1) AU2005227733A1 (es)
BR (1) BRPI0509382A (es)
CA (1) CA2561400A1 (es)
IL (1) IL178064A0 (es)
MA (1) MA28558B1 (es)
NO (1) NO20064884L (es)
PE (1) PE20060678A1 (es)
TW (1) TW200536814A (es)
WO (1) WO2005095328A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
JP5645762B2 (ja) * 2010-06-29 2014-12-24 日本ポリプロ株式会社 ポリオレフィンの結晶性分布分析方法およびその装置
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2678338B1 (en) 2011-02-25 2015-09-09 Novartis AG Pyrazolo[1,5-a]pyridines as trk inhibitors
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AT396333B (de) 1982-10-08 1993-08-25 Glaxo Group Ltd Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer
NL8601949A (nl) * 1985-07-30 1987-02-16 Glaxo Group Ltd Inrichtingen voor het toedienen van medicamenten aan patienten.
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1993019749A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5495054A (en) * 1994-05-31 1996-02-27 Sepracor, Inc. Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9700226D0 (en) * 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
ES2331119T3 (es) 2002-09-16 2009-12-22 Glaxo Group Limited Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist

Also Published As

Publication number Publication date
WO2005095328A1 (en) 2005-10-13
EP1730104A1 (en) 2006-12-13
KR20070000508A (ko) 2007-01-02
AU2005227733A1 (en) 2005-10-13
BRPI0509382A (pt) 2007-09-18
US20100063157A1 (en) 2010-03-11
CA2561400A1 (en) 2005-10-13
NO20064884L (no) 2006-10-26
TW200536814A (en) 2005-11-16
IL178064A0 (en) 2006-12-31
US7846973B2 (en) 2010-12-07
JP2007530652A (ja) 2007-11-01
PE20060678A1 (es) 2006-08-02
MA28558B1 (fr) 2007-04-03

Similar Documents

Publication Publication Date Title
AR052301A1 (es) Procedimiento de preparacion de un monoclorhidrato. formas cristalinas y composiciones farmaceuticas
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
PH12015500236A1 (en) 1, 4-disubstituted pyridazine analogs and methods for treating smn-deficiency - related conditions
NO20073743L (no) Forbindelser med Kv4 ionekanal aktivitet
IN2014KN00948A (es)
MX2009011823A (es) Piridonacarboxamidas, agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion.
UA99908C2 (ru) Пиридопиразиновые производные, способ борьбы с растениями, гербицидные композиции
BR112014027181A2 (pt) derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
CO6220955A2 (es) Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
GB2456096A (en) Crystalline form of benzothiophene compound and process for preparation thereof
BRPI0712312A2 (pt) Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
MX2023000693A (es) Inhibidor de egfr.
NO20073549L (no) Fremgangsmate for fremstilling av organiske forbindelser
BR112023024037A2 (pt) Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal